Leap Therapeutics Inc
NASDAQ:LPTX

Watchlist Manager
Leap Therapeutics Inc Logo
Leap Therapeutics Inc
NASDAQ:LPTX
Watchlist
Price: 0.3572 USD 1.77% Market Closed
Market Cap: 14.8m USD

Operating Margin
Leap Therapeutics Inc

0%
Current
-1 901%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-71.1m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Leap Therapeutics Inc
NASDAQ:LPTX
14.8m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
337.9B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
165.8B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
141.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.6B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
130.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Leap Therapeutics Inc
Glance View

Market Cap
14.8m USD
Industry
Biotechnology

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.

LPTX Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-71.1m
/
Revenue
0
What is the Operating Margin of Leap Therapeutics Inc?

Based on Leap Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top